Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses

The total duration of the study period per participants was 46 weeks comprising 3 periods: * a 4-week screening period, * a 36-week double-blind treatment period, * a 6-week post-treatment follow-up period. Participants who successfully completed the double-blind treatment phase were offered the possibility to continue study treatment in the extension study LTS6048 - NCT00228163.